Methods of treating diseases with human trophoblast stem cells

• US 9,927,426 B2
• Filed: 08/31/2015
• Issued: 03/27/2018
• Est. Priority Date: 02/24/2005
• Status: Active Grant

• Current Assignee: Accelerated Biosciences Corp.
• Original Assignee: Accelerated Biosciences Corp.
• Inventors: Lee, Jau-Nan, Lee, Tony Tung-Ying, Lee, Yuta
• Primary Examiner(s): Kelly, Robert M
• Application Number:
  US14/840,970
• Publication Number:
  US 20160051592A1
• Time in Patent Office: 939 Days
• Field of Search: None
• CPC Class Codes: A61K 35/12 Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells vaccines or medicinal preparations containing antigens or antibodies A61K39/00
• CPC Class Codes: A61K 35/39 Pancreas; Islets of Langerhans Langerhans cells of epidermis A61K35/36
• CPC Class Codes: A61K 35/54 Ovaries; Ova; Ovules; Embryos; Foetal cells; Germ cells
• CPC Class Codes: A61K 39/395 Antibodies agglutinins A61K38/36 ; as drug carriers A61K47/50; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
• CPC Class Codes: C12N 2500/34 Sugars
• CPC Class Codes: C12N 2500/38 Vitamins
• CPC Class Codes: C12N 2500/44 Thiols, e.g. mercaptoethanol
• CPC Class Codes: C12N 2501/115 Basic fibroblast growth factor (bFGF, FGF-2)
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 2533/54 Collagen; Gelatin
• CPC Class Codes: C12N 5/0605 Cells from extra-embryonic tissues, e.g. placenta, amnion, yolk sac, Wharton's jelly
• CPC Class Codes: C12N 5/0606 Pluripotent embryonic cells, e.g. embryonic stem cells [ES] embryonic germ cells C12N5/0611, induced pluripotent stem cells C12N5/0696
• CPC Class Codes: C12N 5/0677 Three-dimensional culture, tissue culture or organ culture; Encapsulated cells
• CPC Class Codes: G01N 33/5073 Stem cells

Abstract

Existence of human trophoblast stem (hTS) cells has been suspected but unproved. The isolation of hTS cells is reported in the early stage of chorionic villi by expressions of FGF4, FGFR-2, Oct4, Thy-1, and stage-specific embryonic antigens distributed in different compartments of the cell. hTS cells are able to derive into specific cell phenotypes of the three primitive embryonic layers, produce chimeric reactions in mice, and retain a normal karyotype and telomere length. In hTS cells, Oct4 and fgfr-2 expressions can be knockdown by bFGF. These facts suggest that differentiation of the hTS cells play an important role in implantation and placentation. hTS cells could apply to human cell differentiation and for gene and cell-based therapies. Disclosed herein are methods for treating diseases, including neurodegenerative diseases, with neural stem cells differentiated from the hTS cells such as those expressing Oct4, SSEA-1, SSEA-3, and SSEA-4.

Claims

1. A method for treating progressive loss of neurons, comprising directly administering to a striatum region of the brain of a subject in need thereof a neural stem cell differentiated from an isolated from an isolated human trophoblast stem cell, wherein the isolated human trophoblast stem cell expresses markers Oct4, SSEA-1, SSEA-3, and SSEA-4, whereby the progressive loss of neurons is treated.

2. The method of claim 1, wherein the administering is by an injection.

3. The method of claim 1, wherein the administering is by a surgical operation.

4. The method of claim 1, further comprising administering to the subject in need thereof an additional therapeutic compound.

5. The method of claim 4, wherein the additional therapeutic compound is an immunosuppressive agent.

6. The method of claim 1, wherein the subject in need thereof is a human.

7. The method of claim 1, wherein the isolated human trophoblast stem cell is induced with retinoic acid to differentiate into the neural stem cell.